Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18709351rdf:typepubmed:Citationlld:pubmed
pubmed-article:18709351lifeskim:mentionsumls-concept:C0205281lld:lifeskim
pubmed-article:18709351lifeskim:mentionsumls-concept:C1417170lld:lifeskim
pubmed-article:18709351lifeskim:mentionsumls-concept:C0522523lld:lifeskim
pubmed-article:18709351pubmed:issue9lld:pubmed
pubmed-article:18709351pubmed:dateCreated2008-9-4lld:pubmed
pubmed-article:18709351pubmed:abstractTextMinimally invasive percutaneous nephrolithopaxy (MIP) was developed to combine the excellent stone-free rates of the conventional percutaneous nephrolithopaxy (PCNL) technique with the low morbidity of the miniaturized PCNL (Mini-Perc) and, at the same time, achieve a high level of patient comfort. The procedure is characterized not only by the diameter of the miniaturized 18-Fr Amplatz sheath that was adopted from the Mini-Perc but also by the following features: ultrasound-guided puncture of the kidney; single-step dilatation of the access tract; ballistic lithotripsy; a low-pressure irrigation system together with stone retraction by irrigation with a specially designed nephroscope sheath, for the so-called vacuum cleaner effect; and a sealed and tubeless access tract with primary closure of the channel independent of hemorrhage and without a second-look procedure.The results of the first 57 patients demonstrate primary stone-free rates of 92.9% with operating times averaging 62 (25-123) min. Severe complications, such as sepsis or bleeding requiring blood transfusion, did not occur. The high and predictable stone-free rate and a low morbidity comparable to that of ureteroscopy and extracorporeal shock-wave lithotripsy make MIP an attractive option for patients and urologists. The "vacuum cleaner effect" with quick removal of stone fragments reduces operating time and prevents new stone formation by avoiding residual fragments. The direct and primary closure of the access tract increases patient comfort and is justified by the reintervention rate of less than 8% in the presented cohort.The lack of a need for second-look nephroscopies, the vacuum cleaner effect, improved patient comfort without nephrostomy tubes, as well as surgery times comparable to that of traditional PCNL demonstrate a consequent evolution of the Mini-Perc. MIP therefore represents a promising and future-oriented module in modern stone therapy.lld:pubmed
pubmed-article:18709351pubmed:languagegerlld:pubmed
pubmed-article:18709351pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18709351pubmed:citationSubsetIMlld:pubmed
pubmed-article:18709351pubmed:statusMEDLINElld:pubmed
pubmed-article:18709351pubmed:monthSeplld:pubmed
pubmed-article:18709351pubmed:issn0340-2592lld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:SchillingDDlld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:StenzlAAlld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:KuczykMMlld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:SievertK DKDlld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:NagelsGGlld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:AnastasiadisA...lld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:MerseburgerA...lld:pubmed
pubmed-article:18709351pubmed:authorpubmed-author:WalcherUUlld:pubmed
pubmed-article:18709351pubmed:issnTypePrintlld:pubmed
pubmed-article:18709351pubmed:volume47lld:pubmed
pubmed-article:18709351pubmed:ownerNLMlld:pubmed
pubmed-article:18709351pubmed:authorsCompleteYlld:pubmed
pubmed-article:18709351pubmed:pagination1066, 1068-73lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:meshHeadingpubmed-meshheading:18709351...lld:pubmed
pubmed-article:18709351pubmed:year2008lld:pubmed
pubmed-article:18709351pubmed:articleTitle[Minimally invasive percutaneous nephrolitholapaxy (MIP)].lld:pubmed
pubmed-article:18709351pubmed:affiliationKlinik für Urologie, Universitätsklinikum, Tübingen, Deutschland. udo.nagele@med.uni-tuebingen.delld:pubmed
pubmed-article:18709351pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18709351pubmed:publicationTypeEnglish Abstractlld:pubmed